Prestige Consumer Healthcare, Inc. (PBH)

44.32 -8.96 (-16.82%) USD  |  NYSE  |  Nov 05, 16:00
44.32 0.00 (0.00%) Pre-Market: 20:00
More

Prestige Consumer Healthcare SG&A Expense (TTM) : 213.07M for Sept. 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2004. Start Trial.
Date Value
September 30, 2026 213.07M
June 30, 2026 279.81M
March 31, 2026 265.23M
December 31, 2025 263.91M
September 30, 2025 258.31M
June 30, 2025 259.05M
March 31, 2025 263.93M
December 31, 2024 263.86M
September 30, 2024 265.20M
June 30, 2024 263.82M
March 31, 2024 259.47M
December 31, 2023 254.02M
September 30, 2023 245.51M
June 30, 2023 249.67M
March 31, 2023 252.42M
December 31, 2022 258.63M
September 30, 2022 267.89M
June 30, 2022 270.61M
March 31, 2022 265.86M
December 31, 2021 261.35M
September 30, 2021 254.61M
June 30, 2021 240.36M
March 31, 2021 226.13M
December 31, 2020 229.64M
September 30, 2020 225.03M
Date Value
June 30, 2020 227.48M
March 31, 2020 236.31M
December 31, 2019 228.29M
September 30, 2019 228.41M
June 30, 2019 228.30M
March 31, 2019 232.85M
December 31, 2018 234.60M
September 30, 2018 236.65M
June 30, 2018 236.76M
March 31, 2018 232.99M
December 31, 2017 245.72M
September 30, 2017 241.49M
June 30, 2017 227.69M
March 31, 2017 217.50M
December 31, 2016 194.08M
September 30, 2016 189.33M
June 30, 2016 186.30M
March 31, 2016 183.22M
December 31, 2015 179.49M
September 30, 2015 181.02M
June 30, 2015 188.83M
March 31, 2015 180.92M
December 31, 2014 169.68M
September 30, 2014 157.79M
June 30, 2014 143.28M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Supernus Pharmaceuticals, Inc. 509.26M
Phibro Animal Health Corp. 249.60M
Structure Therapeutics, Inc. 74.01M
ANI Pharmaceuticals, Inc. 324.76M
Corcept Therapeutics, Inc. 432.49M